HYDERABAD, India — Dr. Reddy’s Laboratories Ltd. and Bayer have partnered to market and distribute a second brand of vericiguat in India. Under the terms of their agreement, Bayer has granted nonexclusive rights to Dr. Reddy’s under the brand name Gantra. Vericiguat, a soluble guanylate cyclase (sGC) stimulator, in India, is indicated, along with guideline-based
HYDERABAD, India — Dr. Reddy’s Laboratories Ltd. has entered into an exclusive partnership with Sanofi Healthcare India Private Ltd. to promote and distribute the latter’s vaccine brands across private markets in India. Under the arrangement, Dr. Reddy’s will have exclusive rights to promote and distribute Sanofi’s well established and trusted paediatric and adult vaccine brands
HYDERABAD, India — Dr. Reddy’s Laboratories, a global pharmaceutical company, has introduced Versavo (bevacizumab) in the United Kingdom. Dr. Reddy’s Versavo is a biosimilar of Avastin and indicated for the treatment of several types of cancers, including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer,
HOUSTON — Dr. Reddy’s Laboratories is collaborating with Coya Therapeutics Inc. to develop and commercialize an investigational combination therapy for the treatment of amyotrophic lateral sclerosis (ALS). Coya has granted Dr. Reddy’s an exclusive license to commercialize Coya 302, a proprietary co-pack kit containing a combination of low dose IL-2 and CTLA-4 Ig (abatacept) in
HYDERABAD, India – Dr. Reddy’s Laboratories Ltd. has been recognized for gender equality and sustainability in multiple rankings. The drugmaker has been included in the Bloomberg Gender-Equality Index (GEI) 2023 for a sixth consecutive year. It is the only Indian pharma company on the list, which includes 484 companies representing 11 sectors, 45 countries and a
HYDERABAD, India – Dr. Reddy’s Laboratories Ltd. announced the recognition of its largest manufacturing facility in Hyderabad as part of the Global Lighthouse Network (GLN) by the World Economic Forum (WEF). “With this recognition, the facility joins the GLN, a community of over 100 manufacturers that are showing leadership in applying Fourth Industrial Revolution (Industry
PRINCETON, N.J. — Dr. Reddy’s Laboratories recently announced the launch, in the U.S. market, of lenalidomide capsules, a therapeutic equivalent generic version of REVLIMID (lenalidomide) Capsules approved by U. S. Food and Drug Administration. With this volume-limited launch, Dr. Reddy’s is eligible for first-tomarket, 180 days of generic drug exclusivity for lenalidomide capsules in 2.5
PRINCETON, N.J. – Dr. Reddy’s Laboratories has acquired U.S. rights to Slayback Pharma’s brimonidine tartrate ophthalmic solution 0.025%, the private label equivalent of Lumify. The-counter eye drop can be used to relieve redness due to minor eye irritations. The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S. Slayback is the
Milan Kalawadia, who has oversight for product management/marketing for U.S. generics for Dr. Reddy’s Laboratories, has been with the company for over a decade and a half. In this interview he details his responsibilities for Dr. Reddy’s extensive U.S. operations, as well as exploring the challenges of the pandemic. He also discusses the company’s relationship
PRINCETON, N.J. — Dr. Reddy’s Laboratories recently announced the launch of Icosapent Ethyl Capsules, 1 gram approved by the U.S. Food and Drug Administration. Dr. Reddy’s Icosapent Ethyl Capsules, 1 gram is approved for the following indication: as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL)
HYDERBAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratoriesannounced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to bring this important product to market at this time,” says Marc
Intellectual property has been essential to the research and development of today’s medicines and will lead to the development and treatment of new medicines addressing still unmet needs. IP is at the core of the health system, as it powers the financing model for R&D. Never has this been more important than today, as the
NEW YORK — Dr. Reddy’s has approached the COVID-19 pandemic with its customary patient-centric philosophy to continue supplying products as quickly as possible. Vincent Colicchio, vice president of supply chain and external manufacturing for Dr. Reddy’s Laboratories North America, says the challenge was to maintain production from the company’s manufacturing sites in its home country
PRINCETON, N.J. — Dr. Reddy’s Laboratories announced the launch of febuxostat tablets, a therapeutic equivalent generic version of Uloric (febuxostat) tablets approved by the U.S. Food and Drug Administration (USFDA). The Uloric brand and generic had U.S. sales of approximately $108 million MAT for the most recent twelve months ending in October 2020 according to
